STOCK TITAN

Taysha Gene Therapies Inc - TSHA STOCK NEWS

Welcome to our dedicated news page for Taysha Gene Therapies (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Taysha Gene Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Taysha Gene Therapies's position in the market.

Rhea-AI Summary
Taysha Gene Therapies reports positive results for TSHA-102 in Rett syndrome trial, with improvements in key efficacy measures and no serious adverse events. FDA clears IND application for pediatric patients. Private placement financing of $150 million extends cash runway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
188.23%
Tags
-
Rhea-AI Summary
Taysha Gene Therapies announces private placement financing of approximately $150 million led by RA Capital Management, extending cash runway into Q3 2025. Proceeds to support clinical development and program activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
188.23%
Tags
none
-
Rhea-AI Summary
Taysha Gene Therapies receives positive recommendation to continue Phase 1/2 trial for gene therapy TSHA-102 in Rett syndrome patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
Taysha Gene Therapies Inc

Nasdaq:TSHA

TSHA Rankings

TSHA Stock Data

549.83M
100.06M
24.77%
69.83%
9.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Dallas

About TSHA

taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.